Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical TrialTarek Hassanein, Dean Tai, Chenghai Liu, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
Annals of Internal Medicine|April 5, 2016
Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort StudyAdrian Reuben, Holly Tillman, Robert J Fontana, et al.
Pageof 4